Skip to content
Friday 21 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,748.16
+0.04%
DAX
25,983.04
0.00%
CAC 40
8,453.09
0.00%
STOXX 50
6,422.06
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Tuesday 23 April 2024 8:58 am  |  Updated:  Tuesday 23 April 2024 9:07 am

This may hurt: English High Court set for Moderna and Pfizer/BioNTech Covid battle starting today

By: Maria Ward-Brennan

Professional Services Editor

Add as a preferred source on Google
This may hurt: London High Court set for Modern and Pfizer/BioNTech covid battle
This may hurt: London High Court set for Modern and Pfizer/BioNTech covid battle. Photo credit Mufid Majnun

The English part of a global dispute billion dollar legal case involving big pharma giants Moderna, Pfizer and BioNTech over Covid patents, kicks off today.

Back in 2020 when Covid was spreading around the world, US pharma giant Modern’s mRNA vaccine was approved and issued for emergency use throughout the US.

The company made headline news after it said it wouldn’t enforce its patents related to Covid-19 vaccines during the pandemic, in an effort to not deter other companies and researchers from making similar vaccines. It later changed that position, limiting it to vaccines manufactured for low and middle-income countries.

The Massachusetts-based pharma company issued a lawsuit against US Pfizer and German BioNTech over allegedly breaching its patents. Commenting at the time, Moderna said it believed that Pfizer and BioNTech’s Covid vaccine infringed patents Moderna filed between 2010 and 2016 covering its mRNA technology.

Moderna claim suggests that it doesn’t want to remove Pfizer’s and BioNTech’s vaccines from the market, but instead, it wants compensation and damages.

This comes after the American company made more than $6bn (£5.7bn) in revenue during the pandemic. The company saw its turnover shoot up to $6.1bn (£7.6bn) for the Q1 of 2022, compared to $1.9bn (£1.5bn) for the same period in 2021.

Both Pfizer and BioNTech fired back and launched a counterclaim against Moderna claiming its patents are invalid and should be revoked.

The lawsuit has also been filed in the US, Germany and the Netherlands. Earlier this month, Pfizer won a pause on the litigation in the Massachusetts Federal Court, as the parties await a decision from the US Patent Office.

While the US is on hold, England is going full stream ahead. The trial kicks off on Tuesday and is set to last under four weeks at the Chancery Division of the High Court in London.

The hearing will be split into two parts, first will be the technical part which will look at the patents, while the second part will be looking at Moderna’s 2020 pledge.

The trial is in front of Mr Justice Meade at the Rolls Building. US giant Moderna has enlisted a team from magic circle law firm Freshfields, while, Pfizer has called on Taylor Wessing and BioNTech has instructed Powell Gilbert for their defence (and counterclaim).

For more on law on Morning Wire

Read more

Lufthansa and aviation rivals clash in London court over power outlet profits

Lufthansa aircraft on tarmac with logo visible, showcasing airlines fleet under clear sky in a business news context

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Legal
  • Business

People & Organisations

  • covid
  • High Court
  • Law
  • Medical
  • Patents
  • Pharma
  • Vaccine

Related Topics

  • Covid

Trending Articles

  • House prices in wealthy London boroughs fall by up to £300,000

  • As it happened: Miners fuel FTSE 100 recovery; oil jumps as Trump claims Strait of Hormuz

  • City law firm sues prominent Emirati business family

  • Amanda Blanc has worked her magic at Aviva

  • As it happened: FTSE 100 rallies after JD Sports drags on blue chips; oil jumps again

More from Morning Wire

  • Lufthansa and aviation rivals clash in London court over power outlet profits

    Legal
    Lufthansa aircraft on tarmac with logo visible, showcasing airlines fleet under clear sky in a business news context
  • Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma

    Business Wire
  • City law firm sues prominent Emirati business family

    Lawsuit
    Due to the provided information being incomplete, I am unable to generate specific alt text for the image in question. Ple...
  • Incoming FRC chair sits on board of construction group facing criminal probe

    Accountancy
    Blonde woman in a blue and black patterned jacket smiling in front of a window
  • Law firm at centre of BHP mammoth lawsuit sued by its own funder

    Lawsuit
    UK class actions surge, lawyers perceived as primary beneficiaries, public awareness highest since 2020, report finds
  • English Football League ‘concerned and disappointed’ at PFA legal challenge

    Sport Business
    Sky Bet EFL official match ball on green grass with a white line
  • Elite English firms face uphill battle in fierce New York market

    Legal
    Aerial view of New York City skyline featuring iconic skyscrapers and bustling streets
  • AI Minister: Visa reform key to keeping tech giants in Britain

    AI
    Kanishka Narayan, prominent figure in the news, engaging in a public event or discussion, showcasing leadership and influe...
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook